Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
(2020)
Journal Article
Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., …Aithal, G. P. (2020). Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. Journal of Hepatology, 73(2), 231-240. https://doi.org/10.1016/j.jhep.2020.03.024
Background & Aims:
Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepatic bile acid production.
Method...
Read More about Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.